Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Current Deferred Revenue (2016 - 2025)

Ascendis Pharma A's Current Deferred Revenue history spans 6 years, with the latest figure at $1.3 million for Q4 2023.

  • For Q4 2023, Current Deferred Revenue changed N/A year-over-year to $1.3 million; the TTM value through Dec 2023 reached $1.3 million, changed N/A, while the annual FY2023 figure was $1.3 million, N/A changed from the prior year.
  • Current Deferred Revenue for Q4 2023 was $1.3 million at Ascendis Pharma A, down from $3.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $3.0 million in Q4 2021 and bottomed at $432801.2 in Q4 2020.
  • The 4-year median for Current Deferred Revenue is $1.1 million (2019), against an average of $1.4 million.
  • The largest annual shift saw Current Deferred Revenue tumbled 87.94% in 2019 before it soared 587.49% in 2021.
  • A 4-year view of Current Deferred Revenue shows it stood at $949709.6 in 2019, then tumbled by 54.43% to $432801.2 in 2020, then skyrocketed by 587.49% to $3.0 million in 2021, then plummeted by 57.19% to $1.3 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Current Deferred Revenue are $1.3 million (Q4 2023), $3.0 million (Q4 2021), and $432801.2 (Q4 2020).